引就引全呗 https://www.reuters.com/article/health-coronavirus-brazil-sinovac/sinovacs-vaccine-general-efficacy-less-than-60-in-brazil-trial-report-idUSS0N2II02ZRace for a cure January 11, 20213:10 PMUpdated 6 hours ago Sinovac's vaccine general efficacy less than 60% in Brazil trial - report By Reuters Staff 1 Min Read FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo BRASILIA (Reuters) - The CoronaVac COVID-19 vaccine developed by China’s Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results. Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report “purely speculative.” Reporting by Anthony Boadle; Editing by Leslie Adler Our Standards: The Thomson Reuters Trust Principles.
新闻门户网站UOL周一援引两位看到结果的消息人士的话报道,中国科兴生物技术公司研发的CoronaVac COVID-19疫苗在巴西的临床试验中,一般疗效不到60%。 JANUARY 11, 2021 https://www.reuters.com/article/health-coronavirus-brazil-sinovac/sinovacs-vaccine-general-efficacy-less-than-60-in-brazil-trial-report-idUSS0N2II02Z
一个比一个低
引就引全呗 https://www.reuters.com/article/health-coronavirus-brazil-sinovac/sinovacs-vaccine-general-efficacy-less-than-60-in-brazil-trial-report-idUSS0N2II02Z Race for a cure January 11, 20213:10 PMUpdated 6 hours ago Sinovac's vaccine general efficacy less than 60% in Brazil trial - report By Reuters Staff 1 Min Read FILE PHOTO: A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS/Thomas Peter/File Photo BRASILIA (Reuters) - The CoronaVac COVID-19 vaccine developed by China’s Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results. Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report “purely speculative.” Reporting by Anthony Boadle; Editing by Leslie Adler Our Standards: The Thomson Reuters Trust Principles.
不强制没人打呀。 我哥办公室报名打疫苗,14个人只有2个去了。我的亲戚朋友只要非强制,都说要等。当然,我家乡目前基本没病例
怪不得巴西的数据一直不出来。中国疫苗就不能搞的透明一点吗,这么遮遮掩掩。
帝 先打
領導要起帶頭作用
當初
帝 等了好幾個月 才去武漢
現在 也拖著不肯打
疫苗
帝啊.....
领导带头打也没问题,反正打的什么内容外人也不知道。
領導連打甚麼也不知道
都不敢打 這領導
也就是個
村支書
村支書當
帝
辛苦啊
楼里不是有几个一直在洗嘛。
那前提是大家都关着